A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
- Registration Number
- NCT00908778
- Lead Sponsor
- Vitreoretinal Technologies, Inc.
- Brief Summary
The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
- Subjects with a history of systemic diabetes(type I,or II)
- Subject with a documented history of Non- proliferative Diabetic Retinopathy(NPDR)
- Subjects with no or partial PVD at baseline exam in study eye.
Exclusion Criteria
- Subjects with retinal pathology in the study eye other then (NPDR)
- Subjects with high myopia in the study eye
- Subjects who have monocular vision or central lateral vision of 20/200 or worse BCVA in the non-study eye.
- Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less then 6 months prior to study enrollment.
- Subjects that have either vitrectomy surgery, intavitreal injections, or laser treatments in the study eye.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Vitreosolve I Vitreosolve Intravitreal injection Vitreosolve Vitreosolve Intravitreal injection
- Primary Outcome Measures
Name Time Method Ultrasound, OCT, and clinical exam 6 months
- Secondary Outcome Measures
Name Time Method Ultrasound ,OCT ,Safety, and Clinical Exam 6 months
Trial Locations
- Locations (5)
Hidalgo
🇲🇽Monterrey, Neuvo Leon, Mexico
La Ceguera
🇲🇽San Lucas, Coyoacan, Mexico
LVPEI
🇮🇳Vizag, AP, India
Conde De Valenciana
🇲🇽Mexico City, DF, Mexico
Amrita
🇮🇳Kochi, India